-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Twist Bioscience recently reported that the candidate antibody TB202-3 (CoVIC-094) found internally can effectively bind to a variety of new coronavirus (SARS-CoV-2) variants, including those with E484K, N501Y, D614G, Y453F and K417N mutant strains indicate that this therapeutic antibody may be effective against a variety of COVID-19 mutant strains
The Coronavirus Immunotherapy Alliance (CoVIC) confirmed that TB202-3 completely blocked the binding of SARS-CoV-2 spike protein to human ACE2 through blind analysis
The results of this research titled "Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study" were published in the journal Science on September 23
Erica Ollmann Saphire, chairman of the alliance and professor at the La Jolla Institute of Immunology, said: “In order to determine the most effective treatment for COVID-19, CoVIC analyzed more than 250 therapeutic antibodies from 46 groups.
There is a key site on the spike protein (S protein) called the receptor binding domain (RBD)
SARS-CoV-2 is an RNA virus that survives by replicating in a human host
If the therapeutic antibody binds to the virus at a site that is not affected by the mutation, it is expected to successfully treat a wide range of COVID-19 variants
About 75% of the antibodies in the blood are IgG
The VHH single domain nanobody developed by Twist only needs one domain on the heavy chain antibody to recognize the target
In addition, Twist has also developed a new type of VHH single domain antibody TB339-031, which is similar in structure and potency to TB202-3, and can also bind to and neutralize the Delta and Epsilon mutants
Dr.
"These combined results indicate that the TB202-3 antibody may be more resistant to receptor-driven selection pressure, so the Twist antibody may have a therapeutic effect on the newly emerged SARS-CoV-2 variants
Previous studies have shown that in the preclinical hamster challenge model, the smallest dose (1 mg/kg) of TB202-3 antibody can prevent weight loss, which is a key indicator of disease severity
###
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
SCIENCE · 23 Sep 2021 · DOI: 10.
